Bessemer Group Inc. Sells 23,776 Shares of DaVita Inc. (NYSE:DVA)

Bessemer Group Inc. cut its position in DaVita Inc. (NYSE:DVA - Free Report) by 77.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,017 shares of the company's stock after selling 23,776 shares during the quarter. Bessemer Group Inc.'s holdings in DaVita were worth $1,073,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Moran Wealth Management LLC grew its holdings in shares of DaVita by 6.2% during the first quarter. Moran Wealth Management LLC now owns 117,204 shares of the company's stock worth $17,929,000 after purchasing an additional 6,882 shares in the last quarter. Asset Management One Co. Ltd. lifted its position in DaVita by 3.5% during the first quarter. Asset Management One Co. Ltd. now owns 20,063 shares of the company's stock valued at $3,069,000 after purchasing an additional 682 shares during the last quarter. Heartland Bank & Trust Co purchased a new position in DaVita in the 1st quarter worth approximately $353,000. Blue Trust Inc. increased its holdings in shares of DaVita by 150.9% in the 1st quarter. Blue Trust Inc. now owns 567 shares of the company's stock worth $87,000 after buying an additional 341 shares during the last quarter. Finally, Precision Wealth Strategies LLC raised its position in shares of DaVita by 12.2% during the 1st quarter. Precision Wealth Strategies LLC now owns 2,724 shares of the company's stock valued at $417,000 after buying an additional 297 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on DVA. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Truist Financial dropped their price target on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $164.50.

DaVita Trading Down 2.7%

DaVita stock traded down $4.02 during mid-day trading on Wednesday, hitting $142.69. The company's stock had a trading volume of 831,042 shares, compared to its average volume of 809,204. The business has a 50 day moving average price of $139.87 and a 200-day moving average price of $149.37. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.25 and a quick ratio of 1.20. DaVita Inc. has a 12 month low of $131.76 and a 12 month high of $179.60. The stock has a market cap of $10.77 billion, a price-to-earnings ratio of 14.14, a price-to-earnings-growth ratio of 1.01 and a beta of 1.11.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. The company had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 176.11% and a net margin of 6.63%. DaVita's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.26 EPS. As a group, analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.